247 related articles for article (PubMed ID: 18515446)
1. Effects of atomoxetine on subjective and neurocognitive symptoms of nicotine abstinence.
Ray R; Rukstalis M; Jepson C; Strasser A; Patterson F; Lynch K; Lerman C
J Psychopharmacol; 2009 Mar; 23(2):168-76. PubMed ID: 18515446
[TBL] [Abstract][Full Text] [Related]
2. Effect of nicotine lozenges on affective smoking withdrawal symptoms: secondary analysis of a randomized, double-blind, placebo-controlled clinical trial.
Shiffman S
Clin Ther; 2008 Aug; 30(8):1461-75. PubMed ID: 18803988
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of a nicotine (4 mg)-containing lozenge on the cognitive impairment of nicotine withdrawal.
Atzori G; Lemmonds CA; Kotler ML; Durcan MJ; Boyle J
J Clin Psychopharmacol; 2008 Dec; 28(6):667-74. PubMed ID: 19011436
[TBL] [Abstract][Full Text] [Related]
4. Nicotine patches and the subjective effects of cigarette smoking: a pilot study.
Cárdenas L; Busto UE; MacDonald A; Corrigall WA
Can J Clin Pharmacol; 2002; 9(4):175-82. PubMed ID: 12584575
[TBL] [Abstract][Full Text] [Related]
5. Atomoxetine treatment of adults with ADHD and comorbid alcohol use disorders.
Wilens TE; Adler LA; Weiss MD; Michelson D; Ramsey JL; Moore RJ; Renard D; Brady KT; Trzepacz PT; Schuh LM; Ahrbecker LM; Levine LR;
Drug Alcohol Depend; 2008 Jul; 96(1-2):145-54. PubMed ID: 18403134
[TBL] [Abstract][Full Text] [Related]
6. Atomoxetine hydrochloride in the treatment of children and adolescents with attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorder: A placebo-controlled Italian study.
Dell'Agnello G; Maschietto D; Bravaccio C; Calamoneri F; Masi G; Curatolo P; Besana D; Mancini F; Rossi A; Poole L; Escobar R; Zuddas A;
Eur Neuropsychopharmacol; 2009 Nov; 19(11):822-34. PubMed ID: 19716683
[TBL] [Abstract][Full Text] [Related]
7. Comparison of the effects of a 24-hour nicotine patch and a 16-hour nicotine patch on smoking urges and sleep.
Aubin HJ; Luthringer R; Demazières A; Dupont C; Lagrue G
Nicotine Tob Res; 2006 Apr; 8(2):193-201. PubMed ID: 16766412
[TBL] [Abstract][Full Text] [Related]
8. Labetalol treatment enhances the attenuation of tobacco withdrawal symptoms by nicotine in abstinent smokers.
Sofuoglu M; Babb D; Hatsukami DK
Nicotine Tob Res; 2003 Dec; 5(6):947-53. PubMed ID: 14668079
[TBL] [Abstract][Full Text] [Related]
9. Atomoxetine for the treatment of attention-deficit/hyperactivity disorder and oppositional defiant disorder.
Bangs ME; Hazell P; Danckaerts M; Hoare P; Coghill DR; Wehmeier PM; Williams DW; Moore RJ; Levine L;
Pediatrics; 2008 Feb; 121(2):e314-20. PubMed ID: 18245404
[TBL] [Abstract][Full Text] [Related]
10. Tobacco abstinence symptom suppression: the role played by the smoking-related stimuli that are delivered by denicotinized cigarettes.
Buchhalter AR; Acosta MC; Evans SE; Breland AB; Eissenberg T
Addiction; 2005 Apr; 100(4):550-9. PubMed ID: 15784070
[TBL] [Abstract][Full Text] [Related]
11. The effects of a prison smoking ban on smoking behavior and withdrawal symptoms.
Cropsey KL; Kristeller JL
Addict Behav; 2005 Mar; 30(3):589-94. PubMed ID: 15718077
[TBL] [Abstract][Full Text] [Related]
12. Quality of life assessment in adult patients with attention-deficit/hyperactivity disorder treated with atomoxetine.
Adler LA; Sutton VK; Moore RJ; Dietrich AP; Reimherr FW; Sangal RB; Saylor KE; Secnik K; Kelsey DK; Allen AJ
J Clin Psychopharmacol; 2006 Dec; 26(6):648-52. PubMed ID: 17110824
[TBL] [Abstract][Full Text] [Related]
13. The influence of transdermal nicotine on tobacco/nicotine abstinence and the effects of a concurrently administered cigarette in women and men.
Kleykamp BA; Jennings JM; Sams C; Weaver MF; Eissenberg T
Exp Clin Psychopharmacol; 2008 Apr; 16(2):99-112. PubMed ID: 18489014
[TBL] [Abstract][Full Text] [Related]
14. Acute effects of glucose tablets on craving, withdrawal symptoms, and sustained attention in 12-h abstinent tobacco smokers.
Harakas P; Foulds J
Psychopharmacology (Berl); 2002 May; 161(3):271-7. PubMed ID: 12021830
[TBL] [Abstract][Full Text] [Related]
15. Atomoxetine augmentation of cholinesterase inhibitor therapy in patients with Alzheimer disease: 6-month, randomized, double-blind, placebo-controlled, parallel-trial study.
Mohs RC; Shiovitz TM; Tariot PN; Porsteinsson AP; Baker KD; Feldman PD
Am J Geriatr Psychiatry; 2009 Sep; 17(9):752-9. PubMed ID: 19700948
[TBL] [Abstract][Full Text] [Related]
16. Effect of glucose on tobacco withdrawal symptoms in recent quitters using bupropion or nicotine replacement.
McRobbie H; Hajek P
Hum Psychopharmacol; 2004 Jan; 19(1):57-61. PubMed ID: 14716714
[TBL] [Abstract][Full Text] [Related]
17. Precessation treatment with nicotine patch significantly increases abstinence rates relative to conventional treatment.
Rose JE; Herskovic JE; Behm FM; Westman EC
Nicotine Tob Res; 2009 Sep; 11(9):1067-75. PubMed ID: 19567826
[TBL] [Abstract][Full Text] [Related]
18. Atomoxetine for weight reduction in obese women: a preliminary randomised controlled trial.
Gadde KM; Yonish GM; Wagner HR; Foust MS; Allison DB
Int J Obes (Lond); 2006 Jul; 30(7):1138-42. PubMed ID: 16418753
[TBL] [Abstract][Full Text] [Related]
19. A randomized, double-blind study of continuation treatment for attention-deficit/hyperactivity disorder after 1 year.
Buitelaar JK; Michelson D; Danckaerts M; Gillberg C; Spencer TJ; Zuddas A; Faries DE; Zhang S; Biederman J
Biol Psychiatry; 2007 Mar; 61(5):694-9. PubMed ID: 16893523
[TBL] [Abstract][Full Text] [Related]
20. A single-blind, randomized, crossover trial of the effects of a nicotine pouch on the relief of tobacco withdrawal symptoms and user satisfaction.
Thornley S; McRobbie H; Lin RB; Bullen C; Hajek P; Laugesen M; Senior H; Whittaker R
Nicotine Tob Res; 2009 Jun; 11(6):715-21. PubMed ID: 19454549
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
